Discussion and Conclusion
cancer tumor, mutated tumors
PROLIFERATION, METASTATIC BREAST CANCER
HS‐10352 at 6 mg QD was well‐tolerated in patients with HR‐positive, HER2‐negative ABC, and showed preliminary antitumor activity in patients with PIK3CA mutated tumors. These findings support the further clinical development of HS‐10352.HS‐10352 is a novel selective PI3Kα inhibitor showing inhibitory effects on the proliferation of cancer tumor cell lines harboring PIK3CA mutations. This study first evaluated the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of HS‐10352 in patients with HR‐positive, HER2‐negative metastatic breast cancer. The results support further clinical development of HS‐10352.
